Related Experiment Videos
A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines
1Novartis, Oncology Department, Basel, Switzerland. patrick_chene@yahoo.com
Abstract:
The hdm2 protein negatively regulates p53 tumour suppressor activity. Upon binding to p53, hdm2 stimulates p53 degradation and inhibits its transcriptional activity. Moreover, the hdm2 protein is overexpressed in various tumours inactivating p53. We report here that an octamer synthetic peptide derived from p53 inhibits the p53-hdm2 interaction in vitro. In cellular assays, this untagged peptide penetrates tumour cells and induces the accumulation of p53. The accumulation of p53 leads to its activation. Two gene products transcriptionally regulated by p53, p21Waf1/Cip1 and hdm2, are induced in the presence of the peptide. When used with tumour cells that overexpress hdm2, the peptide induces the death of these tumour cells by apoptosis. The mode of action of this peptide differs from that of DNA-damaging agents (e.g. cisplatin) in that it does not induce p53 phosphorylation on serine 15. This work validates with a low molecular mass molecule our current knowledge on the regulation of the p53 pathway by the hdm2 protein. It also shows that inhibitors of the p53-hdm2 interaction are very attractive candidates for the activation of the p53 pathway in tumours expressing wild-type p53.
Insights
A synthetic peptide inhibits the interaction between HDM2 protein and p53 tumor suppressor. This peptide activates p53, leading to apoptosis in tumor cells, offering a new therapeutic strategy for cancer.
Area of Science:
- Molecular Biology
- Cancer Biology
- Drug Discovery
Background:
- The HDM2 protein is a key negative regulator of the p53 tumor suppressor.
- HDM2 promotes p53 degradation and inhibits its activity, and its overexpression is common in various cancers.
- Understanding the p53-HDM2 interaction is crucial for developing novel cancer therapies.
Purpose of the Study:
- To investigate a synthetic peptide derived from p53 as an inhibitor of the p53-HDM2 interaction.
- To evaluate the peptide's ability to activate the p53 pathway and induce tumor cell death.
- To explore the potential of p53-HDM2 interaction inhibitors as anti-cancer agents.
Main Methods:
- In vitro assays to assess the inhibition of p53-HDM2 binding by the synthetic peptide.
- Cellular assays to evaluate peptide penetration, p53 accumulation, and activation.
- Analysis of p53-regulated gene products (p21Waf1/Cip1, hdm2) induction.
- Assessment of apoptosis induction in tumor cells overexpressing hdm2.
Main Results:
- The synthetic peptide effectively inhibits the p53-HDM2 interaction in vitro.
- The peptide penetrates tumor cells and induces p53 accumulation and activation.
- p53-regulated genes, including p21Waf1/Cip1 and hdm2, are upregulated in the presence of the peptide.
- The peptide induces apoptosis in tumor cells overexpressing hdm2, independent of p53 phosphorylation at serine 15.
Conclusions:
- A low molecular mass peptide can disrupt the p53-HDM2 interaction, validating current knowledge of p53 pathway regulation.
- Inhibitors of the p53-HDM2 interaction are promising candidates for activating the p53 pathway in wild-type p53 expressing tumors.
- This approach offers a distinct mechanism of action compared to DNA-damaging agents for cancer therapy.